Zhai LY - Search Results

1

Effect of the combination of a cyclooxygenase-1 selective inhibitor and taxol on proliferation, apoptosis and angiogenesis of ovarian cancer in vivo.

Li W, Liu ML, Cai JH, Tang YX, Zhai LY, Zhang J. Li W, et al. Among authors: zhai ly. Oncol Lett. 2012 Jul;4(1):168-174. doi: 10.3892/ol.2012.688. Epub 2012 Apr 23. Oncol Lett. 2012. PMID: 22807982 Free PMC article.

2

Cyclin D1 expression and the inhibitory effect of celecoxib on ovarian tumor growth in vivo.

Li W, Jiang HR, Xu XL, Wang J, Zhang J, Liu ML, Zhai LY. Li W, et al. Among authors: zhai ly. Int J Mol Sci. 2010 Oct 19;11(10):3999-4013. doi: 10.3390/ijms11103999. Int J Mol Sci. 2010. PMID: 21152316 Free PMC article.

3

Combined effects of cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on ovarian carcinoma in vivo.

Li W, Wang J, Jiang HR, Xu XL, Zhang J, Liu ML, Zhai LY. Li W, et al. Among authors: zhai ly. Int J Mol Sci. 2011 Jan 18;12(1):668-81. doi: 10.3390/ijms12010668. Int J Mol Sci. 2011. PMID: 21340007 Free PMC article.

4

Antitumor properties of taxol in combination with cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on ovarian tumor growth in vivo.

Li W, Zhai L, Tang Y, Cai J, Liu M, Zhang J. Li W, et al. Oncol Res. 2012;20(2-3):49-59. doi: 10.3727/096504012x13473664562466. Oncol Res. 2012. PMID: 23193911

5

Effects of SC-560 in combination with cisplatin or taxol on angiogenesis in human ovarian cancer xenografts.

Li W, Wan L, Zhai LY, Wang J. Li W, et al. Among authors: zhai ly. Int J Mol Sci. 2014 Oct 23;15(10):19265-80. doi: 10.3390/ijms151019265. Int J Mol Sci. 2014. PMID: 25342321 Free PMC article.

6

Global status and attributable risk factors of breast, cervical, ovarian, and uterine cancers from 1990 to 2021.

Li T, Zhang H, Lian M, He Q, Lv M, Zhai L, Zhou J, Wu K, Yi M. Li T, et al. J Hematol Oncol. 2025 Jan 10;18(1):5. doi: 10.1186/s13045-025-01660-y. J Hematol Oncol. 2025. PMID: 39794860 Free PMC article.

7

"γδT Cell-IL17A-Neutrophil" Axis Drives Immunosuppression and Confers Breast Cancer Resistance to High-Dose Anti-VEGFR2 Therapy.

Zhang Z, Yang C, Li L, Zhu Y, Su K, Zhai L, Wang Z, Huang J. Zhang Z, et al. Front Immunol. 2021 Oct 15;12:699478. doi: 10.3389/fimmu.2021.699478. eCollection 2021. Front Immunol. 2021. PMID: 34721375 Free PMC article.

8

Effect of anti-COVID-19 drugs on patients with cancer.

Huang W, Liu W, Yu T, Zhang Z, Zhai L, Huang P, Lu Y. Huang W, et al. Eur J Med Chem. 2024 Mar 15;268:116214. doi: 10.1016/j.ejmech.2024.116214. Epub 2024 Feb 9. Eur J Med Chem. 2024. PMID: 38367490 Free article. Review.

9

Prognostic value of systemic inflammatory markers in ovarian Cancer: a PRISMA-compliant meta-analysis and systematic review.

Zhu Y, Zhou S, Liu Y, Zhai L, Sun X. Zhu Y, et al. BMC Cancer. 2018 Apr 18;18(1):443. doi: 10.1186/s12885-018-4318-5. BMC Cancer. 2018. PMID: 29669528 Free PMC article. Review.

10

Tumor-Associated Macrophages (TAMs): A Critical Activator In Ovarian Cancer Metastasis.

Yin M, Shen J, Yu S, Fei J, Zhu X, Zhao J, Zhai L, Sadhukhan A, Zhou J. Yin M, et al. Onco Targets Ther. 2019 Oct 21;12:8687-8699. doi: 10.2147/OTT.S216355. eCollection 2019. Onco Targets Ther. 2019. PMID: 31695427 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

32 results

Search Page

Filters